Abstract
Adaptive servoventilation (ASV) represents the most recent advancement in the treatment of Cheyne-Stokes respiration and other forms of central sleep apnea. ASV interferes with the pathophysiologic changes of hyperventilatory breathing disturbances, and has been proved to most efficiently treat central breathing disturbances in comparison with other positive airway pressure (PAP) options, oxygen, or drugs. However, ASV algorithms need to be refined to sufficiently address nonresponders. Because of its efficacy, ASV can be recommended for the treatment of most central breathing disturbances, especially hyperventilatory disorders, if a first trial of continuous PAP has failed.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
